Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 120, Issue 10, 2013, Pages 1224-1232

  Schnettler, W T ^a,b   Dukhovny, D ^a,b   Wenger, J ^b   Salahuddin, S ^a,b   Ralston, S J ^a,b   Rana, S ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenic factors; costs; pre eclampsia; resource use

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; PLACENTAL GROWTH FACTOR; URIC ACID; VASCULOTROPIN RECEPTOR 1;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; EMERGENCY HEALTH SERVICE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FETAL WELL BEING; GESTATIONAL AGE; HEALTH CARE COST; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MEDICARE; PREECLAMPSIA; PREMATURE LABOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; URIC ACID BLOOD LEVEL; URINARY EXCRETION;

ANGIOGENIC FACTORS; COSTS; PRE-ECLAMPSIA; RESOURCE USE;

ADULT; BIOLOGICAL MARKERS; COSTS AND COST ANALYSIS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84882265726     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.12259     Document Type: Article

References (20)

1. Duley L,. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130-7.
2. Koonin LM, MacKay AP, Berg CJ, Atrash HK, Smith JC,. Pregnancy-related mortality surveillance-United States, 1987-1990. MMWR CDC Surveill Summ 1997; 46: 17-36.
3. Mathers CD, Lopez AD, Murray CJL,. The burden of disease and mortality by condition: data, methods, and results for 2001. In:, Lopez AD, Mathers CD, Ezzati M, et al. editors. Global Burden of Disease and Risk Factors. Washington DC: World Bank; 2006.
4. Sibai BM, Stella CL,. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009; 200: 481.e1-7.
5. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-58.
6. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-83.
7. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3-18.
8. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009; 22: 1021-38.
9. Moore AG, Young H, Keller JM, Ojo LR, Yan J, Simas TA, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med 2012; 25: 2651-7.
10. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125: 911-9.
11. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202: 161.e1-e11.
12. Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 2010; 362: 1282-91.
13. www.cms.gov/apps/physician-fee-schedule. 2013.
14. Hadker N, Garg S, Costanzo C, Miller JD, Foster T, van der Helm W, et al. Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective. J Med Econ 2010; 13: 728-37.
15. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health 2007; 10: 336-47.
16. Stepan H, Schaarschmidt W, Jank A, Verlohren S, Kratzsch J,. Use of angiogenic factors (sFlt-1/PlGF ratio) to confirm the diagnosis of preeclampsia in clinical routine: first experience. Z Geburtshilfe Neonatol 2010; 214: 234-8.
17. Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, Ter Riet G, Duley L, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2008; 12: iii-iv, 1-270.
18. McElrath TF, Lim KH, Pare E, Rich-Edwards J, Pucci D, Troisi R, et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 2012; 207:407. e1-7.
19. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 2012; 119: 778-87.
20. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011; 24: 1187-207.